Fifth Third Bancorp to Participate in the BofA Securities 2025 Financial Services Conference
CINCINNATI, February 04, 2025--(BUSINESS WIRE)--Fifth Third Bancorp (Nasdaq: FITB) will participate in the BofA Securities 2025 Financial Services Conference on February 11, 2025 at approximately 1:50 PM ET. Bryan Preston, executive vice president and chief financial officer will represent the Company.
Audio webcast and any presentation slides may be viewed live and for approximately 14 days after the conference through the Investor Relations section of www.53.com. Additionally, any slides used in the presentation will be made available in a printer-friendly format on the Company's website.
About Fifth Third Bancorp
Fifth Third is a bank that's as long on innovation as it is on history. Since 1858, we've been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it's one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people, and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere's World's Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation's highest performing regional bank, but to be the bank people most value and trust.
Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ® Global Select Market under the symbol "FITB." Investor information and press releases can be viewed at www.53.com.
Category: Conferences
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204554383/en/
Contacts
Matt Curoe (Investor Relations)Matt.Curoe@53.com | 513-534-2345Jennifer Hendricks Sullivan (Media Relations)Jennifer.Hendricks.Sullivan@53.com | 614-744-7693
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
34 minutes ago
- Business Insider
‘Nothing Lasts Forever,' Says Top Investor About Palantir Stock
Palantir (NASDAQ:PLTR) stock presents investors with quite a quandary. Confident Investing Starts Here: On the one hand, there is no denying that the company has delivered incredible growth over the past few years. Its revenues are skyrocketing, its margins are strong, and its list of customers continues to grow by leaps and bounds. Its share price has responded in kind, surging by over 466% over the past twelve months. And therein lies the rub, as PLTR is now trading at elevated multiples that are far and above the sector average. This leads to the question of whether all that company growth has led to enthusiasm that is a bit too optimistic. Top investor Riyado Sofian is decidedly on the fence, and is not sure which way the winds will blow. 'It's hard to decide whether to buy or sell — best to just hold it,' states the 5-star investor, who is in the top 3% of TipRanks' stock pros. Sofian outlines the bull case, describing a company that has introduced game-changing AI technology that sets the firm apart from its peers. Beyond the growing sales, profits, and customers, the investor also points out that revenues from Palantir's top 20 customers increased by 26% year-over-year, a strong indication of customer satisfaction. While the company continues to raise its guidance, it often succeeds in going well beyond these numbers, notes Sofian, and it has repeatedly 'destroyed its guidance' in previous quarters. In other words, more massive growth could be on the horizon for Palantir. 'All things considered, this is execution on an elite level — there's no denying it,' adds Sofian. And yet, judging by traditional metrics, the company is overvalued, the investor acknowledges, and its narrative as 'the most important AI company in the West' is what has powered its continuing ascent. For that reason, as long as the company's growth continues apace, PLTR should continue to rise as well. However, that is far from certain, and at a valuation of 100x its revenues, there is practically no room for error if the impressive rate starts to slow. To this point, Sofian reminds investors that nothing lasts forever. With neither a Buy nor a Sell looking particularly appealing, Sofian is splitting the difference and rating PLTR shares a Hold (i.e. Neutral). (To watch Sofian's track record, click here) That stance is echoed across Wall Street. Of the 18 analyst reviews on file, 11 say Hold, while just 3 recommend Buy and 4 suggest Sell, making PLTR a consensus Hold. The average 12-month price target sits at $101.06, implying a ~23% downside from current levels. (See PLTR stock forecast) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
VinFast Auto Ltd (VFS) Q1 2025 Earnings Call Highlights: Record Deliveries Amid Financial Challenges
Net Revenue: USD657 million, a 150% increase year-over-year. Cost of Goods Sold: USD888 million, a 113% increase year-over-year. Gross Margin: Minus 35%, improved from minus 59% last year. SG&A Expenses: USD51 million, a 23% increase year-over-year. R&D Expenses: USD81 million, down 22% year-over-year. EBITDA: Minus USD396 million, with an EBITDA margin of minus 60%. Net Loss: Minus USD712 million, with a net loss margin of minus 109%. CapEx: USD147 million, down 24% year-over-year. Operating Cash Flow: Minus USD607 million. Liquidity: USD2.4 billion, including loans and grants. EV Deliveries: 36,330 vehicles, a 296% increase year-over-year. Two-Wheeler Deliveries: 44,904 units, a 473% increase year-over-year. Warning! GuruFocus has detected 4 Warning Signs with VFS. Release Date: June 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. VinFast Auto Ltd (NASDAQ:VFS) reported a significant increase in vehicle deliveries, with a 296% year-over-year growth in electric vehicle deliveries for Q1 2025. The company achieved a notable improvement in gross margin, moving from minus 59% in the same period last year to minus 35% in Q1 2025. VinFast is expanding its market presence in Southeast Asia, with strong growth in Vietnam and strategic partnerships in Indonesia and the Philippines. The company is investing in new vehicle platforms and E/E architecture to drive cost efficiencies and improve product offerings. VinFast has secured substantial financial support, with liquidity standing at approximately USD2.4 billion, including loans and grants from Vingroup and its founder. Despite improvements, VinFast Auto Ltd (NASDAQ:VFS) reported a net loss of USD712 million for Q1 2025, highlighting ongoing financial challenges. The company is facing a decline in quarter-over-quarter vehicle deliveries, with a 32% drop in electric vehicle deliveries compared to the previous quarter. VinFast is closing direct-to-consumer showrooms in North America and Europe, indicating potential challenges in these markets. The company recorded a USD20 million impairment charge related to the closure of showrooms, with expectations of additional charges in the coming quarters. VinFast's cost of goods sold remains high, at 135% of revenue for the quarter, indicating ongoing pressure on profitability. Q: Can you provide the timeline for the new factories in Vietnam, India, and Indonesia, and their impact on production capacity? A: All facilities in Asia are expected to start operations this year. The India factory will open in July, followed by Hai Phong and then Indonesia. These facilities will focus on more affordable models, while the existing Vietnam facility will handle high-end models. Q: What are the key catalysts for VinFast's growth in the coming years? A: VinFast is focusing on scaling operations, accelerating product development, and executing cost optimization. We aim to double vehicle deliveries in 2025 and maintain momentum into 2026, driven by deeper market penetration and new CKD manufacturing facilities. Our next-generation products will be more cost-effective, and 2025 is a foundational investment year for our platforms and zonal architecture. Q: Could you elaborate on the decision to pivot into the bus market and the expected timeline for bus deliveries? A: We have started delivering buses in Vietnam and expect to deliver around 1,000 this year. We are expanding into other markets like Indonesia, Europe, the Middle East, and the US, gradually capturing growth in electric bus penetration. Q: What is the expected trajectory of average selling prices (ASPs) for the rest of the year? A: The ASP for Q1 2025 was around USD15,000, similar to Q4 2024. For the full year 2025, ASP is likely to remain under USD20,000, with smaller models like VF 3 and VF 5 contributing significantly to deliveries. Q: Can you share more details on the new vehicle platform and E/E architecture? A: Our next-generation vehicle platform focuses on cost efficiency, commonality, and modularity. The new E/E architecture reduces wiring complexity and enhances software scalability. We are also redesigning top hats to align with the platform, reducing costs and improving manufacturing efficiency. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion," said Mike Blue, President and CEO, HistoSonics. The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:
